So much promise seemingly being squandered, perhaps tragic and truly a shame. (Fouremm)
Absolutely!!!
Let's revisit this:
ClinicalTrials.gov Identifier: NCT04894266
Recruitment Status : Recruiting
First Posted : May 20, 2021
Last Update Posted : November 1, 2021
Study start date
The actual date on which the first participant was enrolled in a clinical study. The "estimated" study start date is the date that the researchers think will be the study start date.
Estimated Study Start Date : November 1, 2021
Estimated Primary Completion Date : March 22, 2022
Estimated Study Completion Date : September 22, 2022
So, with an updated November 1, 2021 posting - and an estimated Study Start date of November 1, 2021...not some far out projection this time, what can we/should we conclude about the earlier guidance given by IR that they would inform the shareholder base when dosing started?
Either, supply chain issues (laughable excuse by now...apabetalone capsules stuck in Hope, BC???)...or did they backtrack and decide not to inform us? 17 days later and we're still out of the loop as to what is really going on here!
Shhhh now, but I've been following these numbers in Edmonton.
The trend has been our friend, but are any of these numbers tied to apabetalone dosing?
That's the big question!
AND RVX isn't talking!